Comparing immunotherapy before, during, or after surgery for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares giving immunotherapy at different times around surgery for stage II-IIIA non-small cell lung cancer. The goal is to find the best time to use this treatment to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage II or IIIA non-small cell lung cancer that can be removed with surgery.
- Your cancer does not have EGFR or ALK mutations (specific genetic changes).
- You are in good general health (able to care for yourself) and have normal organ function.
- You have not had prior treatment for this lung cancer, such as chemotherapy, radiation, or immunotherapy.
- You do not have active infections, autoimmune diseases, or other serious medical conditions that would make the trial unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
This study looks at using immunotherapy before surgery for stage II-III lung cancer. It aims to find markers that predict how well this treatment works, potentially leading to more personalized care.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
Hear when a new Resectable Stage II-IIIa NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.